TY - JOUR
T1 - Potential adverse effects of proton pump inhibitors
AU - Coté, Gregory A.
AU - Howden, Colin W.
N1 - Funding Information:
Dr. Cote has received an investigator-initiated grant from Astra-Zeneca Pharmaceuticals. Dr. Howden has served as a consultant for and received speaker honoraria from Santarus, has received speaker honoraria and grant support from AstraZeneca Pharmaceuticals, and has served as a consultant for TAP Pharmaceutical Products.
PY - 2008
Y1 - 2008
N2 - Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease over the past two decades. Among the most commonly prescribed agents worldwide, PPIs' overall safety profile is unquestionable. However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more than the minimum effective dose to older adult patients) may help to further limit the impact of some of these possible adverse effects.
AB - Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease over the past two decades. Among the most commonly prescribed agents worldwide, PPIs' overall safety profile is unquestionable. However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more than the minimum effective dose to older adult patients) may help to further limit the impact of some of these possible adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=54049091656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54049091656&partnerID=8YFLogxK
U2 - 10.1007/s11894-008-0045-4
DO - 10.1007/s11894-008-0045-4
M3 - Review article
C2 - 18625128
AN - SCOPUS:54049091656
SN - 1522-8037
VL - 10
SP - 208
EP - 214
JO - Current gastroenterology reports
JF - Current gastroenterology reports
IS - 3
ER -